NCT04419649 : A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAplastic Anaemia,Myelodysplasia

Trial Overview Read MoreRead more

This phase II trial is evaluating the effects of a new drug on anemia, in patients who have very low, low or intermediate risk Myelodysplastic Syndromes (MDS) .
 

This trial is treating patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Commercial Sponsor

Keros Therapeutics

Summary

Eligible participants will be assigned to receive either escalating or a confirmed dose of KER-050, subcutaneously, every 4 weeks for up to 4 cycles.

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next